Abstract 172P
Background
PLCE1 has been identified as a susceptibility gene for ESCC. However, the precise involvement of PLCE1 in glycolysis and its impact on anti-tumor immunity remain elusive.
Methods
We conducted an analysis of DEG) in ESCC cell lines following the silencing of PLCE1 using Affymetrix GeneChip technology. We employed IP-MS to identify molecules interacting with PLCE1, which are also associated with glycolytic processes. The mechanisms were further probed through a combination of IP assays, in vivo tumor growth experiments, and ubiquitination assays. To study the role of PLCE1 in glycolysis and its impact on anti-tumor immunity, we established an ESCC-induced model in C57BL/6 mice with the PLCE1-/- genotype, utilizing the carcinogen 4NQO.
Results
Bioinformatics analysis revealed that DEGs were significantly enriched in cell metabolism, particularly the glycolysis pathway. Knockdown of PLCE1 led to the suppression of glycolysis in ESCC cell lines through the regulation of ENO1 expression, a key enzyme in glycolysis. This effect was observed both in vitro and in vivo. Additionally, we have elucidated a novel pathway in which PLCE1 interacted with CDK2 and ENO1 to enhance the phosphorylation and stability of ENO1. Phosphorylation of ENO1 effectively prevented its ubiquitination and proteasome-mediated degradation, which was orchestrated by FBXW7-a recognized E3 ubiquitin ligase. In human ESCC tissues, we observed an increase in the population of CD8+ T cells in close proximity to PLCE1+ENO1+ tumor cells. A heightened accumulation of CD8+ PD1+ T cells was noted around these PLCE1+ENO1+ tumor cells. In an ESCC-induced mice model, a more pronounced infiltration of both CD4+ T cells and CD8+ T cells was observed in the PLCE1-/- genotype. Notably, T cells within the PLCE1-/- genotype exhibited heightened cytokine production and lower PD1 expression, an effect that was further potentiated by the ENO1 inhibitor.
Conclusions
Our study demonstrates that PLCE1 has the capacity to interact with CDK2 and ENO1, thereby counteracting FBXW7-mediated ubiquitination of ENO1. This intricate mechanism leads to an augmentation of glycolysis in ESCC and fosters an immune-suppressive tumor microenvironment.
Legal entity responsible for the study
The authors.
Funding
Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display